Did you know? BIB can build out a custom facility for you with our patented, revolutionary PanFlex engineering! Unlike conventional methods, PanFlex-Engineering adopts a bottom-up approach, building facilities based on clients' needs, increasing usage, and reducing costs. Learn more about our groundbreaking collaboration with 89bio to manufacture pegozafermin, addressing unmet medical needs in metabolic dysfunction-associated steatohepatitis (MASH). Our partnership exemplifies innovation, efficiency, and transformative business in the biotech industry. About: Boston Institute of Biotechnology, LLC (BIB) has recently entered into a groundbreaking collaboration agreement with 89bio (NASDAQ: ETNB) to construct a state-of-the-art production facility for the manufacturing of pegozafermin, a potential treatment for metabolic dysfunction-associated steatohepatitis (MASH). Under the terms of the agreement, BIB's sister company, BiBo Biopharma Engineering, will spearhead the construction of the production facility. This facility will be specifically designed to supply 89bio with pegozafermin for commercialization, pending approval. Key Achievements and Impact: The collaboration represents a transformative business partnership between BIB and 89bio, aiming to address the unmet medical needs of patients suffering from MASH. By leveraging BIB's extensive experience in contract manufacturing and engineering expertise, the deal enables the establishment of a cutting-edge production facility dedicated to pegozafermin. The construction of the facility aligns with 89bio's strategic vision to secure manufacturing capacity to meet commercial demand for pegozafermin, based on promising mid-stage study results. Summary: This transformative partnership not only showcases BIB's expertise in CMC services but also highlights its pivotal role in advancing innovative therapies for complex diseases. https://lnkd.in/eA62cPqd #Biotech #Innovation #PanFlex #Collaboration #BIB #89bio
Boston Institute of Biotechnology, LLC’s Post
More Relevant Posts
-
Discover the transformative trends shaping the Big Pharma industry in 2024, from the rise of biologics to the impact of AI and gene therapies. Explore how these innovations are revolutionizing drug development, enhancing patient care, and driving operational efficiency. Stay ahead with insights into personalized medicine, real-world data utilization, and strategic collaborations. #BigPharmaTrends #BiologicsRevolution #AIinPharma #GeneTherapyBreakthroughs #PersonalizedMedicine #RealWorldDataInsights #OperationalEfficiency #PatientCare #PharmaInnovation #CollaborativeHealthcare
Latest Emerging Trends on The Big Pharma Industry
Boston Institute of Biotechnology, LLC on LinkedIn
-
BIO 2024 was more than just presentations and panels – it was a hub of networking opportunities! From valuable connections to fruitful collaborations, BIO 2024 was a catalyst for growth. We unveiled our latest innovations, from next-generation bioreactors to advanced analytics. Explore how our cutting-edge solutions are driving efficiency and performance in biomanufacturing. #BIO2024Tech #BiotechInnovation #CDMO #BIO2024Networking #BiotechPartnerships
-
-
Missed BIO 2024? Don't worry, we've got you covered! Check out our recap of the key highlights from this year's conference. From groundbreaking discoveries to insightful discussions, BIO 2024 was a game-changer for the biotech industry. ◾ Explore how BIB's unmatched capabilities in microbial fermentation and mammalian cell culture can revolutionize your bioproduction journey. ◾ Learn about our cutting-edge facilities, including the world's first ultra-large bioreactor of 30,000L, designed for your success. ◾ Dive into the innovative PanFlex Platform, streamlining the deployment of customized bioprocessing facilities. ◾ Discover how we're driving down costs by up to 80% per gram product, making biomanufacturing more accessible than ever. Connect with us or send a message to contactus@bostonbib.com post-BIO 2024 to unlock limitless possibilities in biotech! #BIO2024 #BiotechConference #CDMOInsights #Innovation
-
-
It’s the first day of the BIO International Convention in San Diego today! Stop by our booth #5357 or send us a message at contactus@bostonbib.com to learn how we transform molecules into medicines helping patients in need! Abbie Watts Arthur Michaud Colin Lambert Atlan Jahed #BIO #CDMO #bioprocess #biomanufacturing
-
-
We are thrilled to be featured in Frost & Sullivan's latest article, spotlighting our leadership in the fourth wave of biologics manufacturing with the world’s first 30,000-liter ultra-large production platform. Key Highlights: -> Massive Scale Production: Leveraging 30,000-liter bioreactors, reaching a total capacity of one million liters. -> Innovative Technology: Our PanFlex® system is redefining ultra-large-scale mammalian cell production. -> Cutting-Edge Facilities: Our state-of-the-art biopharmaceutical production base is nearing completion, placing us at the forefront of industrial transformation. 💡 Why It Matters: This revolution enables more efficient, large-scale biologics production, making life-saving therapies more accessible and affordable for patients globally. As biologics demand soars, our innovative approach will address capacity shortages and drive the industry forward. Join us on this incredible journey towards a healthier future! 📖 Read the full article here: https://lnkd.in/eVCW-eSj Bibo Biopharma is proud to be a sister company of BIB. Though separate entities, we collaborate globally, sharing resources under the same leadership team. #Biopharma #Biologics #Innovation #Healthcare #BiboPharma #CDMO #Biotechnology #LifeSciences
The Fourth Revolutionary Wave of Biologics Manufacturing: CDMOs Empower Large-scale Production of Biologics
https://www.frost.com
-
Revolutionizing Biologic Medicine: Tackling High Costs and Enhancing Access Biologic medicines, crucial for treating various severe health conditions, come with a hefty price tag—ranging from $10,000 to $30,000 per year per patient. Between 2013 and 2021, U.S. spending on biologics surged by 160%, from $100 billion to $260 billion. Despite representing only 0.4% of prescriptions, biologics account for a staggering 46% of all drug spending in the U.S. This financial burden is significant: a 2022 survey found that one in nine Medicare beneficiaries skips biologic prescriptions due to cost. For cancer patients, high-priced biologics can comprise 50-60% of treatment expenses, leading over 40% to exhaust their life savings within two years of diagnosis. At the Boston Institute of Biotechnology, we are committed to changing this narrative by driving down costs and increasing access to life-saving biologics: 🔬 World's Largest Bioreactors We've introduced ultra large-scale bioreactors for mammalian and microbial production, achieving economies of scale that significantly lower manufacturing costs for biologics, vaccines, and cell therapies. ⚙️ PanFlex Bioprocess Engineering Our PanFlex platform allows rapid, cost-effective deployment of customized bioprocessing facilities, reducing construction time and costs by 50%, thus speeding up the availability of new therapies. Through these innovations, we aim to enhance productivity, reduce costs, and expand access to transformative healthcare solutions globally. Join us in our mission to improve lives worldwide. Connect with us to explore partnerships or career opportunities: https://lnkd.in/eBJrBiN Sources: https://lnkd.in/ezje4iZa https://lnkd.in/gAfcidrw #Biotech #HealthcareInnovation #Biologics #AffordableMedicine #Bioprocessing #BostonBiotech #CDMO #AllianceManagement #BiotechPartner
-
-
Check out our research into process development from the preclinical stages of gene therapy to commercialization: "Strategies to Accelerate Process Development from Preclinical to Manufacturing for Gene Therapy" The purpose of this study was to show the increased interest in gene therapies and the production challenges that arise with them. BIB has developed strategies to mitigate these challenges and accelerate the process development. Study can be found here: https://lnkd.in/gyun8C4B Authors: WengLong Roy Lin, Dogan Ornek, Chi Ming Yu, Nida Sayed Zubairy Stay tuned for more updates! Follow our LinkedIn page for the latest news and feel free to reach out to us with any questions.
Title: Strategies to Accelerate Process Development from Preclinical to Manufacturing for Gene Therapy - Boston Institute of Biotechnology
https://bostonbib.com
-
Boston Institute of Biotechnologys Director of MSAT Chi Ming Yu along with Business Development Specialist Colin Lambert presented BIBs Ultra-Large Scale Biomanufacturing capabilities this week at the Protein Engineering Summit in Boston! Learn more about seamless Technology Transfer and our PanFlex system on our website. Find more information here: https://lnkd.in/ewBBqDfJ #PEGS2024 #Biotechnology #Biomanufacturing #TechTransfer #BIB #30000L
-
